^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG CLASS:
Proton pump inhibitor
DRUG CLASS:
Proton pump inhibitor
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
12d
Tegoprazan-containing Sequential for H. Pylori (clinicaltrials.gov)
P=N/A, N=400, Recruiting, Seoul National University Bundang Hospital
New trial
12d
Combined effect of pantoprazole and mesenchymal stem cells on experimentally induced gastric ulcer: implication of oxidative stress, inflammation and apoptosis pathways. (PubMed, Inflammopharmacology)
Histopathological investigation of gastric tissue revealed moderate to slight histopathological alterations and almost normal histological features of the epithelial cells, gastric mucosal layer, muscularis mucosa and submucosa in PANTO-, ADSCs- and ADSCs + PANTO-treated rats, respectively. Conclusively, the co-treatment with ADSCs and PANTO evidenced sententious physiological protection against GU by suppressing oxidative stress, inhibiting inflammation and reducing apoptosis with consequent acceleration of gastric tissue healing process.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • ICAM1 (Intercellular adhesion molecule 1) • CASP3 (Caspase 3) • TGFB1 (Transforming Growth Factor Beta 1) • MMP9 (Matrix metallopeptidase 9) • PCNA (Proliferating cell nuclear antigen) • PPARG (Peroxisome Proliferator Activated Receptor Gamma)
13d
A Study to Evaluate the Impact of Lactobacillus Rhamnosus GG on Proton Pump Inhibitor-Induced Gut Dysbiosis (clinicaltrials.gov)
P=N/A, N=30, Recruiting, Mayo Clinic | Trial completion date: Mar 2024 --> Dec 2024 | Trial primary completion date: Mar 2024 --> Dec 2024
Trial completion date • Trial primary completion date
13d
A Trial of Omeprazole and Low Dose Aspirin to Identify Colorectal Biomarkers of Preventive Efficacy (clinicaltrials.gov)
P1, N=24, Not yet recruiting, University of Michigan Rogel Cancer Center
New P1 trial
|
CASP3 (Caspase 3)
15d
Efficacy and safety of proton pump inhibitors on cardiovascular events and inflammatory factors in patients with upper gastrointestinal bleeding undergoing dual antiplatelet therapy. (PubMed, Inflammopharmacology)
Melena was the most frequent clinical manifestation in UGIB patients. The use of PPIs did not increase the risk of CVEs, and different PPI drugs did not affect the occurrence of CVEs. Furthermore, PPIs lowered CRP and TNF-α levels in serum of these patients.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • CRP (C-reactive protein)
24d
Biomarkers for Prediction of Analgesic Efficacy in Knee OA. (clinicaltrials.gov)
P=N/A, N=17, Completed, Rambam Health Care Campus | Recruiting --> Completed | N=100 --> 17 | Trial completion date: Dec 2023 --> Apr 2024 | Trial primary completion date: Aug 2023 --> Apr 2024
Trial completion • Enrollment change • Trial completion date • Trial primary completion date
24d
Assessment of Gastric pH Changes Induced by Ascorbic Acid Tablets (clinicaltrials.gov)
P1, N=11, Active, not recruiting, Indiana University | Recruiting --> Active, not recruiting | Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2025
Enrollment closed • Trial completion date • Trial primary completion date
24d
Role of Proton Pump Inhibitors on the Postoperative Course Following Pancreaticoduodenectomy (clinicaltrials.gov)
P2, N=56, Active, not recruiting, Washington University School of Medicine | Recruiting --> Active, not recruiting | N=330 --> 56 | Trial completion date: Jul 2025 --> Jun 2024 | Trial primary completion date: Jul 2025 --> Jun 2024
Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
25d
Metformin and Esomeprazole in Preterm Pre-eclampsia (clinicaltrials.gov)
P4, N=4, Active, not recruiting, Christiana Care Health Services
New P4 trial
|
metformin
1m
ARMV: Anti-reflux Mucosal Valvuloplasty Versus PPIs for GERD Treatment (clinicaltrials.gov)
P=N/A, N=74, Not yet recruiting, Qilu Hospital of Shandong University
New trial
1m
EERENs: Esomeprazole and Radiation Induced Esophagitis (clinicaltrials.gov)
P2, N=48, Recruiting, Rush University Medical Center | Not yet recruiting --> Recruiting
Enrollment open
1m
Efficacy and Safety of Tegoprazan Dual Therapy and Furazolidone-based Bismuth Quadruple Therapy for Helicobacter Pylori Eradication: A Prospective, Multicenter, Open-label, Randomized Controlled Clinical Study (clinicaltrials.gov)
P=N/A, N=600, Not yet recruiting, Nanjing First Hospital, Nanjing Medical University
New trial
1m
Proton pump inhibitors enhance macropinocytosis-mediated extracellular vesicle endocytosis by inducing membrane v-ATPase assembly. (PubMed, J Extracell Vesicles)
PPI-induced macropinocytosis also increases doxorubicin and antisense oligonucleotides of microRNA-155 delivery efficiency by EVs, leading to enhanced therapeutic effects of drug-loaded EVs on tumours and acute liver failure. Mechanistically, PPIs reduce cytosolic pH, promote ATP6V1A (v-ATPase subunit) disassembly from the vacuolar membrane and enhance the assembly of plasma membrane v-ATPases, thereby inducing macropinocytosis. Altogether, our results reveal a mechanism for macropinocytic regulation and PPIs as potential modulators of EV levels, thus regulating their functions.
Journal
|
MIR155 (MicroRNA 155)
|
doxorubicin hydrochloride
1m
The Safety and Tolerability, Pharmacokinetics of TNP-2092 Capsules in Combination With Rabeprazole Sodium Enteric-coated Tablets (clinicaltrials.gov)
P1, N=20, Completed, TenNor Therapeutics Inc.
New P1 trial • Combination therapy
1m
PK, PD and Safety of Tegoprazan 12.5 mg After Oral Administration in Healthy Subjects (clinicaltrials.gov)
P1, N=36, Enrolling by invitation, HK inno.N Corporation
New P1 trial
2ms
Re-EValuating the Inhibition of Stress Erosions (REVISE) Trial (clinicaltrials.gov)
P3, N=4800, Completed, McMaster University | Active, not recruiting --> Completed
Trial completion
2ms
Effect of Dexlansoprazole on Bone Homeostasis (clinicaltrials.gov)
P1, N=115, Completed, Takeda | N=247 --> 115
Enrollment change
2ms
Repurposing of US-FDA-approved drugs as negative modulators of ubiquitin specific protease-7 (USP7). (PubMed, Heliyon)
Among the identified 11 hits, compound 6 (oxybutynin), 7 (ketotifen), 10 (pantoprazole sodium), and 11 (escitalopram) also showed anti-cancer activity with an effect on the expression of proto-oncogenes and tumor-suppressor gene at mRNA level in HCT116 cells. The compounds identified in this study can serve as potential leads for further studies.
FDA event • Journal
|
TP53 (Tumor protein P53) • USP7 (Ubiquitin Specific Peptidase 7)
2ms
H. Pylori Screen-and-treat Study in a Population of Young Adults (clinicaltrials.gov)
P=N/A, N=6800, Recruiting, University of Latvia | Not yet recruiting --> Recruiting
Enrollment open
2ms
Argel's stemmoside C as a novel natural remedy for mice with alcohol-induced gastric ulcer based on its molecular mechanistic pathways. (PubMed, J Ethnopharmacol)
These findings cast light on Stemmoside C's clinical application against gastric ulcer progression, recurrence, & tumorigenicity & concurrently with chemotherapy.
Preclinical • Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • JAK1 (Janus Kinase 1) • STAT3 (Signal Transducer And Activator Of Transcription 3) • IL10 (Interleukin 10) • MMP9 (Matrix metallopeptidase 9) • IL1B (Interleukin 1, beta)
2ms
Study to Evaluate the Efficacy and Safety of Ilaprazole 10 mg in Prevention NSAIDs Associated Peptic Ulcer (clinicaltrials.gov)
P3, N=416, Not yet recruiting, Il-Yang Pharm. Co., Ltd.
New P3 trial
2ms
H. Pylori Screen-and-treat Study in a Population of Young Adults (clinicaltrials.gov)
P=N/A, N=6800, Not yet recruiting, University of Latvia
New trial
3ms
Is Long-Term Proton Pump Inhibitor Use a Cause of Leaky Gut Syndrome (clinicaltrials.gov)
P=N/A, N=75, Completed, Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital
New trial
3ms
A Study to Evaluate the Long-Term Safety of BLI5100 in Patients With Gastroesophageal Reflux Disease (clinicaltrials.gov)
P3, N=400, Enrolling by invitation, Braintree Laboratories | Trial completion date: Feb 2025 --> Sep 2024 | Trial primary completion date: Oct 2024 --> Mar 2024
Trial completion date • Trial primary completion date
3ms
A Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Erosive Esophagitis (clinicaltrials.gov)
P3, N=1250, Recruiting, Braintree Laboratories | Trial completion date: Jul 2025 --> Dec 2024 | Trial primary completion date: Dec 2024 --> Jun 2024
Trial completion date • Trial primary completion date
3ms
A Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Non-Erosive Reflux Disease (clinicaltrials.gov)
P3, N=800, Active, not recruiting, Braintree Laboratories | Trial completion date: Nov 2024 --> May 2024 | Trial primary completion date: May 2024 --> Jan 2024
Trial completion date • Trial primary completion date
3ms
Prevention of Recurrent Ulcer Bleeding in Patients With Idiopathic Gastroduodenal Ulcer (clinicaltrials.gov)
P4, N=154, Recruiting, Chinese University of Hong Kong | Trial completion date: Dec 2024 --> Mar 2027 | Trial primary completion date: Dec 2023 --> Dec 2026
Trial completion date • Trial primary completion date
3ms
Treatment of Gastroesophageal Reflux Disease in Infants (clinicaltrials.gov)
P4, N=96, Not yet recruiting, Odense University Hospital
New P4 trial
3ms
Prevention of Post-Cardiac Surgery Acute Kidney Injury by Proton Pump Inhibitor (clinicaltrials.gov)
P4, N=100, Recruiting, The University of Texas Health Science Center, Houston | Not yet recruiting --> Recruiting
Enrollment open • Surgery
|
KIM1 (Kidney injury molecule 1)
3ms
Gastroprotective effect of rhodanine and 2,4-thiazolidinediones scaffolds in rat stomachs by contribution of anti-apoptotic (BCL-2) and tumor suppressor (P53) proteins. (PubMed, Sci Rep)
Likewise, immunohistochemical staining of antiapoptotic (BCL2) and tumor suppressor (P53) proteins showed strong positive marks in the10% Tween 80- treated group, opposing the mild staining results for the esomeprazole-treated group. Similarly, the staining intensity of the group treated with Compounds 2-8 was variable for both proteins.
Preclinical • Journal
|
BCL2 (B-cell CLL/lymphoma 2)
3ms
A Study to Evaluate the Long-Term Safety of BLI5100 in Patients With Gastroesophageal Reflux Disease (clinicaltrials.gov)
P3, N=400, Enrolling by invitation, Braintree Laboratories | Trial completion date: Sep 2024 --> Feb 2025 | Trial primary completion date: Mar 2024 --> Oct 2024
Trial completion date • Trial primary completion date
3ms
A Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Non-Erosive Reflux Disease (clinicaltrials.gov)
P3, N=800, Active, not recruiting, Braintree Laboratories | Trial completion date: May 2024 --> Nov 2024 | Trial primary completion date: Jan 2024 --> May 2024
Trial completion date • Trial primary completion date
3ms
A Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Erosive Esophagitis (clinicaltrials.gov)
P3, N=1250, Recruiting, Braintree Laboratories | Trial completion date: Dec 2024 --> Jul 2025 | Trial primary completion date: Jun 2024 --> Dec 2024
Trial completion date • Trial primary completion date
3ms
Clinical Study of Jinsang Liyan Capsules Combined With PPI in the Treatment of LPRD (clinicaltrials.gov)
P4, N=72, Recruiting, Tongji Hospital | Not yet recruiting --> Recruiting
Enrollment open
3ms
A Study to Compare How Different Substances (Caffeine, Warfarin, Omeprazole, Metoprolol, and Midazolam) Are Handled by the Body of Healthy People and People With Liver Cirrhosis (clinicaltrials.gov)
P=N/A, N=30, Recruiting, Boehringer Ingelheim | Trial completion date: Jun 2024 --> Jan 2025 | Trial primary completion date: May 2024 --> Jan 2025
Trial completion date • Trial primary completion date • Metastases
3ms
Role of Proton Pump Inhibitors on the Postoperative Course Following Pancreaticoduodenectomy (clinicaltrials.gov)
P2, N=330, Recruiting, Washington University School of Medicine | N=240 --> 330
Enrollment change
4ms
Neuropeptide W facilitates chronic gastric ulcer healing by the regulation of cyclooxygenase and NF-κB signaling pathways. (PubMed, Inflammopharmacology)
In conclusion, NPW facilitated the healing of gastric injury in rats via the inhibition of pro-inflammatory cytokine production, oxidative stress and neutrophil infiltration as well as the downregulation of COX-2 protein and NF-κB gene expressions.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • IL1B (Interleukin 1, beta) • MPO (Myeloperoxidase)
|
PTGS2 expression
4ms
Efficacy of pantoprazole plus perforation repair for peptic ulcer and its effect on the stress response. (PubMed, World J Gastrointest Surg)
Therefore, PPZ plus perforation repair is conducive to enhancing treatment outcomes in PU patients, reducing oxidative stress injury and excessive inflammatory reactions, and contributing to low recurrence and complication rates.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • IL1B (Interleukin 1, beta) • CRP (C-reactive protein)
4ms
Efficacy and Safety of Tegoprazan Versus Esomeprazole-containing Bismuth Quadruple Therapy for Eradication of Helicobacter Pylori (clinicaltrials.gov)
P3, N=561, Completed, Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. | Not yet recruiting --> Completed | Trial completion date: Mar 2024 --> Sep 2023 | Trial primary completion date: Mar 2024 --> Sep 2023
Trial completion • Trial completion date • Trial primary completion date
4ms
Prolonged Proton Pump Inhibitor Use and Thrombohemorrhagic Risk in Essential Thrombocythemia and Polycythemia Vera Patients Treated with Long-Term Aspirin: A Pilot Study. (PubMed, Pharmacology)
Considering that Helicobacter pylori infection and PUD are quite frequent in ET and PV patients, these preliminary results may provide some reassurance to physicians regarding the absence of thrombohemorrhagic risk associated with prolonged PPI use in MPN patients treated with long-term aspirin. Our observations may be even more important in the light of recent evidence suggesting suboptimal platelet inhibition in ET with once-daily when compared to twice- or triple-daily aspirin which may also cause more abdominal discomfort. Limitations of this study are its retrospective design, limited number of patients included, and the lack of pharmacodynamic and pharmacokinetic assessments.
Clinical
|
ABL1 (ABL proto-oncogene 1)
4ms
Effect of Acid Suppression Medication on Pediatric Microbiome (clinicaltrials.gov)
P=N/A, N=7, Terminated, Columbia University | N=30 --> 7 | Unknown status --> Terminated; Lack of funding
Enrollment change • Trial termination
4ms
Anti-inflammatory effects of Weiyan I decoction against gastric ulcers in a rat model via inhibition of p38 mitogen-activated protein kinases signaling. (PubMed, Pak J Pharm Sci)
SD rats were divided into control, model, lansoprazole (30mg/kg), SB203580 (2mg/kg), WYI (10.8g/kg, 5.4g/kg and 2.7g/kg) groups. GU was induced using ethanol or indomethacin post-WYI pre-administration...WYI had no significant impact on gastric acid and mucus secretion. WYI demonstrated gastroprotective effects in GU through anti-inflammatory actions and p38 MAPK pathway inhibition, providing insights for innovative GU therapies.
Preclinical • Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL1B (Interleukin 1, beta)
Share via
